XML 48 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment The following table presents certain financial data for the Company’s reportable segment (in thousands):
Three months ended September 30,Nine months ended September 30,
2025202420252024
Clinical trial expenses$1,054 $3,757 $8,491 $9,304 
Employee related research and development expenses2,073 1,995 6,696 6,147 
Chemistry, manufacturing and controls expenses456 476 1,486 3,534 
Other research and development expenses1,458 1,523 3,909 4,849 
Contract and grant reimbursements— (544)(754)(888)
Employee related general and administrative expenses1,333 846 3,782 2,724 
Professional fees and other general and administrative expenses1,670 2,289 5,259 5,837 
Other segment items2,039 8,496 2,9846,387 
Segment net loss$10,083 $18,838 $31,853 $37,894 

September 30,
2025
December 31,
2024
Total segment assets$28,284 $28,178